Erectile Dysfunction - Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com

Erectile Dysfunction - Pipeline Review, H2 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Erectile Dysfunction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
• The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 112 pages “Erectile Dysfunction - Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Erectile Dysfunction - Overview, Erectile Dysfunction - Therapeutics Development, Erectile Dysfunction - Therapeutics Assessment, Erectile Dysfunction - Companies Involved in Therapeutics Development, Erectile Dysfunction - Drug Profiles, Erectile Dysfunction - Dormant Projects, Appendix. This report Covered Companies few are - Astellas Pharma Inc, Biolab Farmaceutica Ltda, Biopharm GmbH, Can-Fite BioPharma Ltd, Fabre-Kramer Pharmaceuticals Inc, Futura Medical Plc, Hanmi Pharmaceuticals Co Ltd, Humanetics Corp, IntelGenx Corp, Ion Channel Innovations LLC, iX Biopharma Ltd.

Please visit this link for more details: http://mrr.cm/UqA

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Phenylketonuria (PKU) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/UqM

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/UqQ